CYP2D6 and breast carcinoma: A total of 25 studies were identified comprising 13,629 patients with breast cancer adding to prior meta-analyses [23,24] by including 5 more studies, providing new insight on a range of outcomes, investigating a potential gene dose-response relationship, and an assessment of data from trials that investigated effect modification of tamoxifen by CYP2D6 genotype status.